Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Cognition Therapeutics (NASDAQ:CGTX) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded Cognition Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 4th. Finally, B. Riley reissued a “buy” rating and issued a $3.00 price target (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Stock Down 2.9%

CGTX opened at $1.00 on Tuesday. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83. The company has a fifty day moving average of $1.45 and a 200-day moving average of $1.56. The stock has a market cap of $88.24 million, a PE ratio of -2.08 and a beta of 1.25.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Sell-side analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Trading of Cognition Therapeutics

A number of hedge funds have recently bought and sold shares of CGTX. Jones Financial Companies Lllp bought a new position in Cognition Therapeutics in the 3rd quarter valued at $25,000. Gamco Investors INC. ET AL purchased a new position in shares of Cognition Therapeutics in the 3rd quarter worth about $27,000. Private Management Group Inc. purchased a new position in shares of Cognition Therapeutics in the 3rd quarter worth about $32,000. CWA Asset Management Group LLC bought a new position in Cognition Therapeutics during the third quarter valued at about $34,000. Finally, Raymond James Financial Inc. increased its holdings in Cognition Therapeutics by 34.7% during the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock worth $40,000 after buying an additional 7,641 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.